AN2 Therapeutics, Inc. (ANTX)

Market Cap	37.65M
Revenue (ttm)	n/a
Net Income (ttm)	-60.70M
Shares Out	29.88M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,268
Open	1.250
Previous Close	1.270
Day's Range	1.235 - 1.280
52-Week Range	0.870 - 22.220
Beta	0.11
Analysts	Hold
Price Target	3.50 (+177.78%)
Earnings Date	Nov 13, 2024

About ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2022
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: ANTX
• Website: https://www.an2therapeutics.com

Analyst Forecast

According to 5 analysts, the average rating for ANTX stock is "Hold." The 12-month stock price forecast is $3.5, which is an increase of 177.78% from the latest price.

Price Target

$3.5

(177.78% upside)

Analyst Consensus: Hold